SEC Form 4 · accession 0001780660-26-000022
Adaptive Biotechnologies Corp · ADPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis Lo
Officer — Chief People Officer
Period of report
Sep 16, 2026
Accepted (ET)
Sep 18, 2026 · 8:17 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001478320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 16, 2026 | M | 53,091 | $12.14 | A | 283,804 | D | |
| Common Stock | Sep 16, 2026 | M | 13,398 | $8.46 | A | 297,202 | D | |
| Common Stock | Sep 16, 2026 | M | 15,629 | $3.99 | A | 312,831 | D | |
| Common Stock | Sep 16, 2026 | M | 23,442 | $8.12 | A | 336,273 | D | |
| Common StockF2 | Sep 16, 2026 | S | 107,537 | $28.02 | D | 228,736 | D | |
| Common StockF3 | Sep 16, 2026 | S | 7,869 | $28.57 | D | 220,867 | D | |
| Common Stock | holding | — | — | — | 2,500 | I | By You Jin Lee (spouse) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $12.14 | Sep 16, 2026 | M | 53,091 | D | — | Mar 4, 2032 | Common Stock | 53,091 | 79,155 | D |
| Stock Option (right to buy)F5 | $8.46 | Sep 16, 2026 | M | 13,398 | D | — | Mar 6, 2033 | Common Stock | 13,398 | 24,113 | D |
| Stock Option (right to buy)F6 | $3.99 | Sep 16, 2026 | M | 15,629 | D | — | Mar 4, 2034 | Common Stock | 15,629 | 65,636 | D |
| Stock Option (right to buy)F7 | $8.12 | Sep 16, 2026 | M | 23,442 | D | — | Mar 4, 2035 | Common Stock | 23,442 | 103,142 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.49 to $28.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4The option is fully vested and exercisable.
- F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F6The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F7The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.